| Dr Thomas Stewart Kelly, DDS | |
|
3700 Park East Dr, Suite 180, Beachwood, OH 44122-4339 | |
| (216) 464-3777 | |
| (216) 464-3377 |
| Full Name | Dr Thomas Stewart Kelly |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 3700 Park East Dr, Beachwood, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215147079 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 30-01-9809 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Stewart Kelly, DDS 3700 Park East Dr, Suite 180, Beachwood, OH 44122-4339 Ph: (216) 464-3777 | Dr Thomas Stewart Kelly, DDS 3700 Park East Dr, Suite 180, Beachwood, OH 44122-4339 Ph: (216) 464-3777 |
News Archive
Automated breast density measurement is predictive of breast cancer risk in younger women, and that risk may be related to the rate at which breast density changes in some women as they age, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA).
Patients who undergo elective total hip or total knee arthroplasty at hospitals with lower surgical volume had a higher risk of venous thromboembolism and mortality following the procedure.
A new process for making a three-dimensional microstructure that can be used in the analysis of cells could prove useful in counterterrorism measures and in water and food safety concerns.
SDI and Cegedim Strategic Data (CSD) announced today that they will jointly launch a new market research service that tracks selling activities in the oncology therapeutic market. The Oncology Selling Audit will be released in January 2011; 2 years of history will be available for reporting and analysis.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 9 days ago
Dr. Jeffrey A. Silver, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 3690 Orange Pl Ste 530, Beachwood, OH 44122 Phone: 216-464-1496 | |
Fredrick A Rosenberg, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 3609 Park East Dr, 411, Beachwood, OH 44122 Phone: 216-464-8985 | |
Dr. Chantal G Whitney, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3401 Richmond Road, Suite 200, Beachwood, OH 44122 Phone: 216-464-1169 Fax: 216-464-1869 | |
Dr. Marcus Castro, DDS Dentist Medicare: Medicare Enrolled Practice Location: 3690 Orange Pl Ste 395, Beachwood, OH 44122 Phone: 216-464-3456 | |
Dr. Abdelazeem Hazem Desoky, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 27060 Cedar Rd, 806, Beachwood, OH 44122 Phone: 216-672-8064 | |
Leone M Pullella, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 3681 Green Rd, 400, Beachwood, OH 44122 Phone: 216-464-7850 Fax: 216-464-7434 | |
Dr. Peter G Gordon, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 23300 Chagrin Blvd, G-10, Beachwood, OH 44122 Phone: 216-464-1180 Fax: 216-464-3707 |